ArticleArthritis research & therapy2026
Serum epitope-specific anti-recoverin autoantibodies as biomarkers for lupus retinopathy.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLupus retinopathy (LR) is a sight-threatening complication of systemic lupus erythematosus (SLE), yet disease-specific serologic biomarkers are lacking. Previous studies have shown that anti-recoverin (RCV) antibodies act as a biomarker of cancer-associated retinopathy and serum level of anti-RCV antibodies was elevated in SLE patients with fundus abnormalities. This study screened three candidate epitopes of RCV protein and evaluated anti-RCV epitope-specific autoantibodies as candidate serological markers for LR.
methodsThe epitopes of RCV protein were predicted by DNAStar software and cross-checked by BepiPred-2.0 and ABCpred. Serum autoantibodies against RCV and three linear epitopes (RCV55–70, RCV139–154, RCV155–170) was determined by ELISA in SLE patients with LR (n = 48), without LR (non-LR, n = 48), and healthy controls (HC, n = 44). Statistical analyses included the Kruskal–Wallis with Dunn’s post-hoc tests, Mann-Whitney U test, Student’s t test, Chi-Square or Fisher’s exact tests, correlation analysis, logistic regression, and ROC analysis.
resultsEpitope-specific anti-RCV antibodies were significantly higher in LR than in non-LR SLE and HC (all p < 0.05). Anti-RCV139–154 demonstrated the highest diagnostic performance for identifying LR from SLE, with an AUC of 0.808 (95% CI: 0.721–0.895), a sensitivity of 54.2% and a specificity of 93.8%, outperforming full-length anti-RCV. Furthermore, anti-RCV139–154 levels positively correlated with SLE disease activity (SLEDAI, r = 0.430, p < 0.001), anti-dsDNA titers, and IgG levels, and inversely correlated with C3 and C4 levels (p < 0.001). Notably, anti-RCV139–154 levels were preferentially elevated in microvasculopathic LR and declined after treatment.
conclusionsEpitope-specific anti-RCV antibodies, especially anti-RCV139–154, may serve as novel biomarkers for early identification of LR in SLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.